Security
Priveterra Acquisition Corp. II Warrant to purchase Class A common stock · PMGMW
PMGMWNASDAQWarrantHistorical · closed May 9, 2024CIK 1837607Updated Oct 27, 2026
Name history
Priveterra Acquisition Corp. · through Jul 24, 2023
Current security for this SEC filerAEON · NYSE_AMERICAN
PMGMW price & chart
Historical security
This listing closed May 9, 2024. Live provider charts are shown only for current listings.
Current security: AEON
About the company
AEON Biopharma is a biopharmaceutical company pursuing full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX®. The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, representing a major opportunity for biosimilar entry. ABP-450 is the same botulinum toxin complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau®. ABP-450 is manufactured by Daewoong Pharmaceutical in a facility that has been authorized by the U.S. Food and Drug Administration, Health Canada, and the European Medicines Agency for the manufacture of certain third-party botulinum toxin products. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. To learn more about AEON, visit www.aeonbiopharma.com.
In the news
No coverage from other publishers is available.
Recent filings
DEF 14A filing
Regulation FD Disclosure
Items 7.01, 9.01
PRE 14A filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
4 filing
Show 5 more recent filings
3 filing
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Other Events
Items 8.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 8,734,000Source | 4,004,000Source | 5,910,000Source | 11,662,000Source | 5,734,000Source | 8,630,000Source | 13,799,000Source | 3,032,000Source | 5,560,000Source | 3,142,000Source | 6,845,000Source | 279,493,625Source |
| Property, Plant and Equipment, NetUSD | 181,000Source | 258,000Source | 123,000Source | 200,000Source | 282,000Source | 142,000Source | 220,000Source | 307,000Source | 162,000Source | 235,000Source | 332,000Source | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 5,927,000Source | 537,000Source | 3,431,000Source | 8,439,000Source | 3,442,000Source | 6,243,000Source | 10,446,000Source | 1,558,000Source | 3,006,000Source | 13,000Source | 5,158,000Source | — |
| Assets, CurrentUSD | 7,412,000Source | 2,371,000Source | 3,993,000Source | 10,262,000Source | 4,019,000Source | 6,625,000Source | 12,321,000Source | 2,498,000Source | 3,398,000Source | 1,590,000Source | 6,222,000Source | 109,196Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,485,000Source | 1,834,000Source | 562,000Source | 1,823,000Source | 577,000Source | 382,000Source | 1,875,000Source | 940,000Source | 392,000Source | 1,577,000Source | 1,064,000Source | — |
| Operating Lease, Right-of-Use AssetUSD | 1,112,000Source | 1,346,000Source | 931,000Source | 1,171,000Source | 1,404,000Source | 992,000Source | 1,229,000Source | 198,000Source | 1,052,000Source | 1,288,000Source | 262,000Source | — |
| Other Assets, NoncurrentUSD | 29,000Source | 29,000Source | 863,000Source | 29,000Source | 29,000Source | 871,000Source | 29,000Source | 29,000Source | 948,000Source | 29,000Source | 29,000Source | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 28,606,000Source | 36,094,000Source | 21,271,000Source | 27,514,000Source | 33,681,000Source | 25,382,000Source | 25,122,000Source | 201,413,000Source | 60,587,000Source | 31,711,000Source | 159,889,000Source | 10,443,306Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 9,000Source | 4,000Source | 10,000Source | 9,000Source | 4,000Source | 10,000Source | 9,000Source | 4,000Source | 9,000Source | 4,000Source | 4,000Source | — |
| Additional Paid in CapitalUSD | 413,801,000Source | 401,585,000Source | 468,396,000Source | 413,283,000Source | 399,557,000Source | 465,850,000Source | 411,170,000Source | 393,235,000Source | 415,783,000Source | 403,024,000Source | 381,264,000Source | 32,000Source |
| Retained Earnings (Accumulated Deficit)USD | -433,682,000Source | -433,679,000Source | -483,767,000Source | -429,144,000Source | -427,508,000Source | -482,612,000Source | -422,502,000Source | -591,620,000Source | -470,819,000Source | -431,597,000Source | -473,602,000Source | -9,469,643Source |
| Stockholders' Equity Attributable to ParentUSD | -19,872,000Source | -32,090,000Source | -15,361,000Source | -15,852,000Source | -27,947,000Source | -16,752,000Source | -11,323,000Source | -198,381,000Source | — | — | -153,044,000Source | -9,436,953Source |
| Liabilities and EquityUSD | 8,734,000Source | 4,004,000Source | 5,910,000Source | 11,662,000Source | 5,734,000Source | 8,630,000Source | 13,799,000Source | 3,032,000Source | 5,560,000Source | 3,142,000Source | 6,845,000Source | 279,493,625Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 8,228,000Source | 10,726,000Source | 7,342,000Source | 9,129,000Source | 10,429,000Source | 6,669,000Source | 8,640,000Source | 15,957,000Source | 6,897,000Source | 14,149,000Source | 13,049,000Source | 3,880,947Source |
| Operating Lease, Liability, CurrentUSD | 247,000Source | 128,000Source | 263,000Source | 242,000Source | 134,000Source | 258,000Source | 197,000Source | 205,000Source | 252,000Source | 121,000Source | 278,000Source | — |
| Accounts Payable, CurrentUSD | 2,525,000Source | 4,630,000Source | 2,697,000Source | 3,907,000Source | 3,030,000Source | 1,481,000Source | 2,437,000Source | 6,523,000Source | 942,000Source | 5,910,000Source | 3,388,000Source | — |
| Operating Lease, Liability, NoncurrentUSD | 957,000Source | 1,204,000Source | 757,000Source | 1,020,000Source | 1,262,000Source | 825,000Source | 1,083,000Source | — | 893,000Source | 1,145,000Source | — | — |
| Other Liabilities, Noncurrent | — | — | —Source | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -11,793,000Source | 9,095,000Source | -39,222,000Source | 42,005,000Source | 6,375,345Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 19,000Source | 19,000Source | 78,000Source | 97,000Source | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,932,000Source | 1,729,000Source | 5,317,000Source | 6,250,000Source | — |
| Changes in operating assets and liabilities: | |||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 539,000Source | -3,473,000Source | -4,968,000Source | 2,522,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -2,636,000Source | -7,909,000Source | -17,308,000Source | -20,292,000Source | -981,428Source |
| Cash flows from investing activities: | |||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | -4,000Source | -4,000Source | — | 401,925Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | 4,000Source | 4,000Source | — | — |
| Cash flows from financing activities: | |||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 5,873,000Source | 18,346,000Source | 20,305,000Source | 15,147,000Source | 150,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 3,237,000Source | 10,433,000Source | 2,993,000Source | -5,145,000Source | -429,503Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 5,927,000Source | 537,000Source | 3,431,000Source | 8,439,000Source | 6,243,000Source | 10,446,000Source | 3,006,000Source | 13,000Source | 67,909Source |
| Additional Financial Items | |||||||||||
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 883,329Source |
| Investment Income, InterestUSD | — | — | — | — | — | — | — | — | — | — | 3,706,667Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -4,538,000Source | -6,171,000Source | -1,155,000Source | -6,642,000Source | -11,793,000Source | 9,095,000Source | -39,222,000Source | 42,005,000Source | 6,375,345Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | -39,222,000Source | 42,005,000Source | — |
| Nonoperating Income (Expense)USD | — | — | -2,045,000Source | -2,155,000Source | 4,764,000Source | -2,304,000Source | -5,860,000Source | 9,557,000Source | -26,419,000Source | -30,980,000Source | 10,584,279Source |
| Operating Costs and ExpensesUSD | — | — | — | — | — | — | — | — | — | — | 3,325,605Source |
| Operating ExpensesUSD | — | — | 2,493,000Source | 4,016,000Source | 5,919,000Source | 4,338,000Source | 5,933,000Source | 462,000Source | 12,803,000Source | -72,985,000Source | — |
| Other Nonoperating Income (Expense)USD | — | — | 68,000Source | 19,000Source | 36,000Source | 92,000Source | 30,000Source | 103,000Source | 290,000Source | 95,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 1,665,000Source | 18,346,000Source | — | 147,000Source | — |
| Share-based Payment Arrangement, Expense | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — |
| Gain (Loss) on Extinguishment of Debt | — | — | — | — | — | — | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General and Administrative ExpenseUSD | — | — | 1,933,000Source | 3,044,000Source | 2,991,000Source | 3,258,000Source | 3,903,000Source | 3,125,000Source | 12,208,000Source | 13,643,000Source | — | — |
| Operating Income (Loss)USD | — | — | -2,493,000Source | -4,016,000Source | -5,919,000Source | -4,338,000Source | -5,933,000Source | -462,000Source | -12,803,000Source | 72,985,000Source | -3,325,605Source | -1,935,943Source |
| Other Nonoperating Income (Expense)USD | — | — | 68,000Source | 19,000Source | 36,000Source | 92,000Source | 30,000Source | 103,000Source | 290,000Source | 95,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -4,538,000Source | -6,171,000Source | -1,155,000Source | -6,642,000Source | -11,793,000Source | 9,095,000Source | -39,222,000Source | 42,005,000Source | 7,258,674Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 883,329Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -4,538,000Source | -6,171,000Source | -1,155,000Source | -6,642,000Source | -11,793,000Source | 9,095,000Source | -39,222,000Source | 42,005,000Source | 6,375,345Source | 8,200,831Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.39Source | -11.24Source | -0.02Source | -0.6Source | -0.29Source | 2.28Source | -3.95Source | 77.74Source | — | — |
| Earnings Per Share, DilutedUSD per share | — | — | -0.39Source | -11.24Source | -0.02Source | -0.6Source | -0.29Source | 2.28Source | -3.95Source | 72.93Source | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 11,634,946Source | 549,175Source | 50,530,946Source | 11,090,809Source | 40,614,087Source | 3,984,876Source | 9,921,587Source | 540,360Source | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 11,634,946Source | 549,175Source | 50,530,946Source | 11,090,809Source | 40,614,087Source | 3,984,876Source | 9,921,587Source | 575,945Source | — | — |
| Additional Financial Items | ||||||||||||
| Investment Income, InterestUSD | — | — | — | — | — | — | — | — | — | — | 3,706,667Source | 79,687Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | -39,222,000Source | 42,005,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | -2,045,000Source | -2,155,000Source | 4,764,000Source | -2,304,000Source | -5,860,000Source | 9,557,000Source | -26,419,000Source | -30,980,000Source | 10,584,279Source | 10,136,774Source |
| Operating Costs and ExpensesUSD | — | — | — | — | — | — | — | — | — | — | 3,325,605Source | 1,935,943Source |
| Operating ExpensesUSD | — | — | 2,493,000Source | 4,016,000Source | 5,919,000Source | 4,338,000Source | 5,933,000Source | 462,000Source | 12,803,000Source | -72,985,000Source | — | — |
| Research and Development ExpenseUSD | — | — | 597,000Source | 972,000Source | 2,938,000Source | 1,064,000Source | 2,034,000Source | 825,000Source | 4,094,000Source | 14,181,000Source | — | — |
Offerings
Registration 333-297327
- Gross proceeds
- 13747516.61
- Net proceeds
- 12880165.61
- Deal price
- 0.3221
- Shares
- 42680896
- Offering price
- $0.3221
- Ticker
- AEON
Registration 333-297439
Registration 333-293309
Filing attachments
aeon-ex99d1.htm · 8-K · 2026-09-30
Exhibit 99.1 PRESS RELEASE AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450 FDA indicated previously completed ABP-450 head-to-head studies versus BOTOX® may be submitted as supportive evidence; AEON expects to advance the required scientific bridging work AEON plans to submit an IND for CMAP pharmacodynamic study in the fourth quarter of 2026 AEON plans to leverage its analytical, pharmacodynamic, and existing comparative human evidence to suppo…
Read attachment ↗aeon-20260812xex99d1.htm · 8-K · 2026-08-12
EX-99.1 2 aeon-20260812xex99d1.htm EX-99.1 Exhibit 99.1 PRESS RELEASE AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advancement of ABP-450's development program - - Upfront proceeds from financing provide cash runway into the first quarter of 2027 - ALISO VIEJO, Calif., August 12, 2026 - AEON…
Read attachment ↗aeon-20260812xex99d2.htm · 8-K · 2026-08-12
EX-99.2 3 aeon-20260812xex99d2.htm EX-99.2 Exhibit 99.2 Disrupting a $3.5B neurotoxin market dominated by a single brand for >30 years CORPORATE PRESENTATION / AUGUST 2026 NYSEAMERICAN: AEON ©2026 AEON BIOPHARMA This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, a…
Read attachment ↗aeon-20260803xex99d1.htm · 8-K · 2026-08-03
EX-99.1 2 aeon-20260803xex99d1.htm EX-99.1 AEON Biopharma Reports Exhibit 99.1 AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards Aliso Viejo, Calif., August 3, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced that it has received written notice f…
Read attachment ↗aeon-20260713xex4d1.htm · 8-K · 2026-07-15
EX-4.1 3 aeon-20260713xex4d1.htm EX-4.1 Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT AEON BIOPHARMA, INC. Warrant Shares: _______Initial Exercise Date: __, 2026 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) until thi…
Read attachment ↗aeon-20260713xex4d2.htm · 8-K · 2026-07-15
EX-4.2 4 aeon-20260713xex4d2.htm EX-4.2 Exhibit 4.2 WARRANT TO PURCHASE COMMON STOCK OR PRE-FUNDED WARRANTS AEON BIOPHARMA, INC. Warrant Shares: _______Issuance Date: July 15, 2026 THIS WARRANT (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after July 15, 2026 (the “Initial Exercise Date”) and on or prior to the earliest…
Read attachment ↗